Vertex Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Vertex reported 3rd quarter 2026 total revenue growth of 12% year over year, with growth of 10% in the U.S. and 16% internationally; results included an approximate 1 percentage point favorable impact from foreign exchange and $10 million of revenue from Kynetics following the acquisition close.
- Global CF revenue grew 8% year over year to $3.3 billion, with 5% growth in the U.S. and 12% outside the U.S., or 10% on a constant currency basis; Aliftrek delivered $706 million in worldwide Q3 sales and served over 18,000 patients around the world.
- Casgevy generated $99 million in Q3 revenue, up 30% sequentially, with approximately 200 infusions completed since launch and over 750 patients initiated worldwide; Vertex said it had infused twice as many patients in the first 9 months of 2026 as in all of 2025.
- Journavix generated $58 million in Q3 revenue and over 750,000 prescriptions, up more than 40% sequentially; more than 1.6 million patients have been treated in the U.S., where it is the number one prescribed branded oral analgesic.
- Palsynify contributed $10 million in September revenue following the acquisition close and approximately $24 million for Q3; approximately 500 endocrinologists are writing prescriptions, and the brand has over 40% share among patients initiating or switching therapy.
- Third-quarter non-GAAP gross margin was 85.6%, non-GAAP net income was $1.21 billion, and non-GAAP earnings per share were $4.76; Vertex ended the quarter with approximately $9.8 billion in cash and investments.
- Third-quarter non-GAAP R&D expense was $936 million, non-GAAP SG&A expense was $556 million, and acquired IP R&D expense was $41 million; Q3 non-GAAP effective tax rate was 18%.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and welcome to the Vertex Pharmaceuticals Third Quarter 2026 Earnings Call. All participants will be in a listen-only mode. Should you need assistance, please signal conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touch-tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead. Good evening all.
My name is Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our Third Quarter 2026 Financial Results Conference Call. On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President, Charlie Wagner, Chief Operating Officer and Chief Financial Officer, and Duncan McKechnie, Chief Commercial Officer. Given the January 1 transition by Charlie to the COO role solely, please note that this is his last quarterly earnings call. His successor, Jonathan Poole, our current SVP of Finance, will join us for our Q4 2026 call in February. We recommend that you access the webcast slides as you listen to this call. The call is being recorded, and a replay will be available on our website.
We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation those regarding Vertex's marketed medicines for cystic fibrosis, sickle cell disease, beta thalassemia, moderate to severe acute pain, and acromegaly, our pipeline, the recently completed acquisition of Crinetics Pharmaceuticals and the expected benefits of that transaction, and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially. I would also note that select financial results and guidance that we will review on the call this evening are presented on a non-GAAP basis. I'll now turn the call over to Reshma.
Thanks, Susie. Good evening all, and thank you for joining us on the call today. I'm pleased to note that Vertex achieved another quarter of excellent commercial results and pipeline advancement. Third quarter total revenue grew 12% year-on-year. Revenue growth was nicely balanced, coming from both the U.S. and international, from CF, and from our two more recently launched medicines, CASGEVY and JOURNAVX, as well as a contribution from PALSONIFY for the month of September, post-close of the Crinetics acquisition. Rare endocrine is now our fourth commercial pillar, and with the PDUFA date later this month for povetacicept in IgA nephropathy, or IgAN, we plan to soon establish our fifth in renal. Before turning to the R&D update, I want to acknowledge Charlie's final and 31st earnings call as CFO. Charlie's leadership, integrity, judgment, and intellectual rigor are unparalleled.
He has deftly helped lead our transition from a CF-only company with $4 billion in revenue in 2019 to a company soon to be commercialized in 5 disease areas with more than triple the revenue, with our guidance for over $13 billion in 2026. I look forward to continuing to work with Charlie in his role as COO, driving forward the Crinetics integration and our key priorities as we grow and scale the company. I can think of no better successor to Charlie than Jonathan Poole, our Senior Vice President and current head of finance, who will take over as CFO January 1, 2027. Moving now to the R&D update for the quarter. I will cover 4 disease areas: CF, endocrinology, both rare endocrine disorders and type 1 diabetes, and renal in detail. First, let me start with quick highlights from 4 other programs.
In severe sickle cell disease and transfusion-dependent beta thalassemia, we were pleased to have recently received approval for CASGEVY in patients ages 2 to 11 in the U.S., U.A.E., Bahrain, as well as in patients ages 5 to 11 in the U.K. In pain, along with the strong growth in prescriptions, we are also seeing fast growth in the body of compelling JOURNAVX real-world data emerge, such as a recent paper detailing 80% or greater freedom from opioid use following total knee replacement when the pain management regimen included JOURNAVX. In chronic pain, both phase III studies in painful diabetic peripheral neuropathy remain on track to complete enrollment by the end of this year, and for us to be able to share results by mid-2027.
In myotonic dystrophy type 1, or DM1, we remain on track to share interim results from the GALILEO global phase I/II clinical trial of VX-670 before the end of the year. In generalized myasthenia gravis, we have completed enrollment of the ETNA phase II dose-ranging study of povetacicept and expect to share proof-of-concept data in the first half of 2027. Moving on to the more detailed R&D review, starting with cystic fibrosis. We see ALYFTREK as the most effective medicine approved for CF. With once-daily dosing, ALYFTREK can treat up to 95% of people with CF, and in our trials, more than 75% of ALYFTREK-treated patients ages 12 and older achieve sweat chloride levels in the range of CF carriers. That is to say, ALYFTREK-treated patients are achieving sweat chloride levels associated with no manifestation of CF disease nor reduced life expectancy.
On the regulatory front, we continue our work to expand to treating younger patients and have initiated global submissions for ALYFTREK approval in children ages 2 to 5. Lastly, in CF, an update on our next-generation 3.0 correctors. We studied VX-828 as part of a triple combination in a cohort of 8 people with CF and as a dual therapy in another cohort of 8. All 16 patients had F/MF mutations, which is a more challenging population to treat than patients with F/F mutations. In this F/MF population, the VX-828 dual combination did not alter sweat chloride relative to the TRIKAFTA baseline. In the triple combination versus a baseline on TRIKAFTA, VX-828 delivered a 6.6 millimole per liter reduction in sweat chloride at day 28, and a 9.4 millimole reduction through day 28. The VX-828 regimen is oral, once daily, with a good safety, tolerability, and DDI profile.
In short, these are excellent results. Given the very high bar set by ALYFTREK, we intend to wait for all the data from the NG 3.0 family of molecules before determining next steps, namely advancement into pivotal development. VX-581 and VX-272, the other NG 3.0 correctors, are currently in first-in-human studies, and the next-gen 4.0 molecules are in late preclinical development. Moving to our newest pillar, rare endocrinology. With the Crinetics acquisition now closed, PALSONIFY in acromegaly is our eighth commercialized medicine, and Duncan will provide details on the ongoing U.S. launch. On the R&D side, the most advanced molecule after PALSONIFY is atumelnant in congenital adrenal hyperplasia, or CAH, which has orphan drug designation in the U.S., E.U., and Japan, and where the phase III pivotal trial is well underway.
The primary efficacy endpoint for this phase III study is the proportion of patients achieving the combination of normalization of androgens and physiologic glucocorticoid dose levels. This is the true goal in CAH therapy, and it is what was demonstrated in the phase II trial. It is also what no other CAH medicine to date has attempted to achieve. In adult CAH, we are targeting completion of enrollment in the phase III study in Q1 2027. The study then calls for 32 weeks of dosing. In pediatric CAH, atumelnant is in a phase II dose-ranging study. Our goal is to rapidly advance the pediatric program into pivotal development following planned regulatory interactions. In addition, the adaptive phase II/III global study of atumelnant in ACTH-dependent Cushing syndrome is already underway outside the U.S. and was recently granted orphan drug designation in the U.S.
We have planned engagements with the FDA to confirm their expectations for this program and look forward to updating you in the coming months. Let me now turn to T1D. After careful analysis, we have chosen to prioritize acceleration of VX-017 as our lead program. Recall, VX-017 is an allogeneic, off-the-shelf, glucose-responsive, insulin-producing, fully differentiated islet cell therapy. It has a similar target product profile to zimislecel, but is designed for people with all blood types. This doubles the eligible patient population to about 120,000 people. The potential to bring transformative benefit to even more patients is the key reason to focus on VX-017, given the resource intensity, complexity, and manufacturing demands of cell therapy programs. We have already begun dosing patients with VX-017 in a phase I/II study.
Our near-term goals are to demonstrate proof of concept and to scale up manufacturing, with the goal of moving to pivotal development next year. Finally, we continue to progress our serial innovation work in T1D, focused on improved immunosuppression and on generating hypoimmune islets, with the goal of making this potentially curative therapy available to even more people. Turning now to renal, where we have four programs in mid and late-stage development. Starting with pove and IgAN, we are both excited and ready for our PDUFA date on November 30th, just weeks away. Duncan will address our launch readiness. We just wrapped up a sparkling ASN annual meeting with the RAINIER phase III interim analysis presentation and publication in the New England Journal of Medicine, supporting what we believe is a differentiated, potentially best-in-class profile for pove in IgAN.
Simply put, pove will offer a trifecta of excellence in efficacy, tolerability, and patient-centric administration features. I will focus tonight just on the patient-centric features. The commercial presentation of pove is clearly differentiated, with a small volume, 0.46 mils, once every four weeks, subcutaneously dosed via auto-injector at home. On this point, this advantage is reflected in the poster presented by If et al. at the recent ASN of a qualitative survey study of about 25 adults with IgAN in the U.S., that revealed 96% of patients preferred an auto-injector relative to injection via a prefilled syringe, and 80% preferred dosing every four weeks versus weekly. Our ambition is to launch pove globally. To that end, we have already completed our filing for potential accelerated approval in the Kingdom of Saudi Arabia, where it has been granted breakthrough status. We estimate KSA represents an incremental 7,000-patient opportunity.
We are planning forward for our regulatory submissions in other regions, including Europe and Asia, when the study completes and the two-year eGFR data are available. On pove in membranous nephropathy, our OLYMPUS phase II/III pivotal trial is ongoing, with phase III enrollment and dosing well underway at the selected dose of 80 milligrams subcutaneously every four weeks. Recall, this study has a 104-week endpoint. On inaxaplin in AMKD, we have two pieces of news since our last earnings call. First, to recap the exciting results from the AMPLIFIED study. In cohort 1 of patients with AMKD and modest proteinuria, treatment with inaxaplin on top of optimized standard of care led to a 42.7% reduction in urine albumin-to-creatinine ratio, or UACR, at week 13 compared to baseline, with the UPCR down 44.7%.
This is remarkably consistent with the treatment effect previously shared in the phase II data in AMKD published in the New England Journal of Medicine. In cohort 2 of people with AMKD and type 2 diabetes, treatment with inaxaplin led to a 17.3% reduction in UACR and a 25.4% reduction in UPCR at week 13. Of note, the majority of patients in both cohorts did not have a diagnosis of FSGS. Inaxaplin was generally safe and well-tolerated with no serious adverse events related to inaxaplin. All adverse events were mild or moderate in severity. We look forward to discussing these results with regulators in the context of the AMPLITUDE study next year. The second key milestone was that we completed full enrollment in the pivotal AMPLITUDE phase II/III trial, and we are fully on track to share the results from the interim analysis of AMPLITUDE early next year.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
16 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
